Ann: Appendix 4C & Quarterly Activity Report - 31 December 2023, page-9

The rate of growth is above projections/guidance. "Revise FY24 revenue guidance to US$36m-40m" is conservative. Hit it or exceed and the money flow is just the start. As a Veteran myself I liked "direct sales of BlastXTM to Long Term Care Centres and Veterans Affairs clinics"

In Australia we have very ultra conservative Doctors. I predict/assume they will be dragged to use NXS innovations in surgery a lot more quickly once legal case(S) by those who get infections get paid out much more as the hospital/surgical infections which would have been avoided IF they had used XPERIENCEtm during surgery and BlastX post surgery as I did four years ago.

Had my leg been chopped off from the nasty infection I had I would have been unable to do that 4 years ago. I only needed the 3rd round of surgery where I used XPERIENCE during surgery and BlastX post surgery due to the infection in my 2nd surgery! It cost me a year delay in my recovery! Compensation cases for avoidable infections are highly likely! A few cases will be enough to drag the slow change in our usually very smart medical systems which are happily risk adverse.



• FY23 Revenue of US$22.2m, up 89.4% on pcp2 with 2H FY23 revenue of US$12.1m
in line with 2H FY23 guidance of US$12m-14m provided in October 2023.
• 4Q FY23 Product Sales of US$7.1m, up 123.5% on pcp reflecting the focus on direct
product sales and introduction of DME3 structure in October 2022.
• 4Q FY23 Direct Product Sales of US$5.6m, up 164.7% on pcp: 79% of product sales.
• Closing cash balance of US$9.2m (30 Sept 2023: US$12.4m) and no debt.
• Reaffirm FY24 guidance to be EBITDA and cashflow positive in 2H FY24.
• Revise FY24 revenue guidance to US$36m-40m. (Previous guidance was for FY24
revenue growth of over 85% year-on-year).